망막모세포종 치료 시장 규모 : 질병 유형, 병기, 치료 유형, 최종 사용자 및 세계 예측(2024-2032년)

Retinoblastoma treatment market size is projected to expand at 4.7% CAGR from 2024 to 2032. The increasing advancements in medical research and technology are making way for early diagnosis and personalized treatment approaches. The rising awareness about retinoblastoma coupled with improved healthcare infrastructure is contributing to higher patient accessibility and treatment rates.

The jump in collaborative efforts among healthcare organizations, research institutions, and pharmaceutical companies is fueling the development of innovative therapies, such as retinoblastoma treatment therapies. The surging focus on pediatric healthcare is leading to several initiatives for promoting early screening and intervention. Additionally, the ongoing investments in oncology research and the growing emphasis on gene therapy and targeted therapies will augment the industry growth.

The retinoblastoma treatment market is segregated into disease type, disease stage, treatment type, end-user, and region.

Based on disease type, the industry value from the hereditary retinoblastoma segment is projected to witness 3.9% CAGR from 2024 to 2032. This is due to the rising advancements in genetic testing for enabling early disease detection. The increasing understanding of genetic factors coupled with the rise in hereditary retinoblastoma cases is amplifying the demand for targeted therapies. Moreover, the ongoing R&D activities, along with the rising focus on personalized medicine will fuel the product demand for treatment of hereditary retinoblastoma.

Retinoblastoma treatment market share from the laser therapy treatment segment is anticipated to rise at 3.7% CAGR from 2024 to 2032, owing to the non-invasiveness and precision of laser therapy for providing effective tumor control. The increasing advancements in laser technology along with its ability to minimize damages to healthy tissues will drive the adoption of various treatment options for retinoblastoma.

Regionally, the Asia Pacific retinoblastoma treatment industry size is projected to depict 5.4% CAGR from 2024 to 2032. The growth can be attributed to the healthcare infrastructure developments, rising awareness about pediatric eye diseases, and improved accessibility to advanced medical treatments. The growing population and the surge in healthcare investments will increase the applications of retinoblastoma treatment in the region. Additionally, the robust collaborative efforts in medical research and advancements in treatment options will also boost the regional industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 Data validation
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Retinoblastoma treatment industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Disease type trends
  • 2.1.4 Disease stage trends
  • 2.1.5 Treatment trends
  • 2.1.6 End-user trends

Chapter 3 Retinoblastoma Treatment Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of retinoblastoma
    • 3.2.1.2 Early diagnosis and treatment of retinoblastoma
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Side effects associated with retinoblastoma treatment
• 3.3 Growth potentialanalysis
  • 3.3.1 By disease type
  • 3.3.2 By disease stage
  • 3.3.3 By treatment type
  • 3.3.4 By end-user
• 3.4 Regulatory landscape
• 3.5 Pipelineanalysis
• 3.6 Porter'sanalysis
• 3.7 PESTELanalysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrixanalysis, 2023
• 4.3 Competitiveanalysis of major market players, 2023
• 4.4 Competitive positioning matrix, 2023
• 4.5 Strategic dashboard, 2023

Chapter 5 Retinoblastoma Treatment Market Estimates and Forecast, By Disease Type, 2018-2032 (USD Million)

• 5.1 Key trends, by disease type
• 5.2 Non-hereditary retinoblastoma
• 5.3 Hereditary retinoblastoma

Chapter 6 Retinoblastoma Treatment Market Estimates and Forecast, By Disease Stage, 2018-2032 (USD Million)

• 6.1 Key trends, by disease stage
• 6.2 Intraocular retinoblastoma
• 6.3 Extraocular retinoblastoma

Chapter 7 Retinoblastoma Treatment Market Estimates and Forecast, By Treatment Type, 2018-2032 (USD Million)

• 7.1 Key trends, by treatment type
• 7.2 Chemotherapy
• 7.3 Radiation therapy
• 7.4 Surgery
• 7.5 Laser therapy
• 7.6 Cryotherapy

Chapter 8 Retinoblastoma Treatment Market Estimates and Forecast, By End-user, 2018-2032 (USD Million)

• 8.1 Key trends, by end-user
• 8.2 Hospitals
• 8.3 Cancer treatment centers
• 8.4 Specialty eye clinics

Chapter 9 Retinoblastoma Treatment Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Baxter International Inc.
• 10.2 Bristol-Myers Squibb Company
• 10.3 GlaxoSmithKline plc
• 10.4 Johnson & Johnson
• 10.5 Merck & Co., Inc.
• 10.6 Novartis AG
• 10.7 Pfizer Inc.
• 10.8 Teva Pharmaceutical Industries Ltd.
• 10.9 Cadila Pharmaceuticals
• 10.10 Cellceutix Corporation